Abstract
The histamine H4 receptor (H4R), recently cloned and identified, is a G-protein coupled histamine receptor family expressed in immune cells which plays an important role in inflammation. Recent data evidentiated that H4R antagonists can decrease airway inflammation and hyperreactivity in animal models of asthma.
In the present study we evaluated the effect of the selective H4R antagonist JNJ7777120 (JNJ) in carrageenan-induced pleurisy, an in vivo model of inflammation, well characterized for cellular and molecular mechanisms.
Intra-pleural administration of λ-carrageenan (1% w/v in 0.2 ml sterile saline) determined an intense recruitment of leucocytes in pleural exudates and in lung tissues, activated inducible nitric oxide (NO) synthase and cyclooxygenase-2, thus increasing the generation of harmful autacoids such as NO and pro-inflammatory prostaglandins, PgE2 and 6-ketoPgF1α, increased cellular and DNA oxidative stress, measured as malondialdehyde and 8-OH-deoxyguanosine and the local generation of IL-1β and TNF-α. Moreover, the activity of caspase-3, an early marker of apoptosis was also activated by λ-carrageenan injection.
The pre-treatment with JNJ (5-10 mg Kg-1 b.wt., given intrapleurally), 60 min before carrageenan markedly reduced all the studied parameters. This study clearly demonstrated that histamine H4R antagonists have anti-inflammatory effects and could have potential therapeutic application for the treatment of inflammatory diseases.
Keywords: Apoptosis, carrageenan, cytokines, inflammation pleurisy, JNJ7777120.
Current Pharmaceutical Design
Title:Effects Of A Selective Histamine H4R Antagonist On Inflammation In A Model Of Carrageenan-Induced Pleurisy In The Rat
Volume: 20 Issue: 9
Author(s): Pini A., Somma T., Formicola G., Lucarini L., Bani D., Thurmond R. and Masini E.
Affiliation:
Keywords: Apoptosis, carrageenan, cytokines, inflammation pleurisy, JNJ7777120.
Abstract: The histamine H4 receptor (H4R), recently cloned and identified, is a G-protein coupled histamine receptor family expressed in immune cells which plays an important role in inflammation. Recent data evidentiated that H4R antagonists can decrease airway inflammation and hyperreactivity in animal models of asthma.
In the present study we evaluated the effect of the selective H4R antagonist JNJ7777120 (JNJ) in carrageenan-induced pleurisy, an in vivo model of inflammation, well characterized for cellular and molecular mechanisms.
Intra-pleural administration of λ-carrageenan (1% w/v in 0.2 ml sterile saline) determined an intense recruitment of leucocytes in pleural exudates and in lung tissues, activated inducible nitric oxide (NO) synthase and cyclooxygenase-2, thus increasing the generation of harmful autacoids such as NO and pro-inflammatory prostaglandins, PgE2 and 6-ketoPgF1α, increased cellular and DNA oxidative stress, measured as malondialdehyde and 8-OH-deoxyguanosine and the local generation of IL-1β and TNF-α. Moreover, the activity of caspase-3, an early marker of apoptosis was also activated by λ-carrageenan injection.
The pre-treatment with JNJ (5-10 mg Kg-1 b.wt., given intrapleurally), 60 min before carrageenan markedly reduced all the studied parameters. This study clearly demonstrated that histamine H4R antagonists have anti-inflammatory effects and could have potential therapeutic application for the treatment of inflammatory diseases.
Export Options
About this article
Cite this article as:
A. Pini, T. Somma, G. Formicola, L. Lucarini, D. Bani, R. Thurmond and E. Masini, Effects Of A Selective Histamine H4R Antagonist On Inflammation In A Model Of Carrageenan-Induced Pleurisy In The Rat, Current Pharmaceutical Design 2014; 20 (9) . https://dx.doi.org/10.2174/13816128113199990553
DOI https://dx.doi.org/10.2174/13816128113199990553 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Recent Patents Concerning Therapy of Respiratory Diseases Using Gene Silencing by RNAi (RISC) and EGS (RNAse P)
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Molecular Modeling Study on Diazine Indole Acetic Acid Derivatives for CRTH2 Inhibitory Activity
Combinatorial Chemistry & High Throughput Screening A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies
Current Drug Therapy Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Children with Medical Complexity: Forwarding a Policy Agenda
Current Pediatric Reviews Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Editorial [Hot Topic: New Drug Targets for the Treatment of Asthma (Guest Editor: D. Knight)]
Current Drug Targets Colloidal Carriers for Ophthalmic Drug Delivery
Current Drug Targets Lipid-Activated Nuclear Receptors and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Aerosol Drug Administration with Helium-Oxygen (Heliox) Mixtures: An Overview
Current Respiratory Medicine Reviews Atopy and Role of Mast Cells in IgE-Mediated Allergic Diseases
Current Immunology Reviews (Discontinued) Curcumin and Immunity
Current Bioactive Compounds Omalizumab in the Therapy of Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Anti-Angiogenetic Agents from the Sea: A New Potential Preventive and Therapeutic Wave?
Anti-Cancer Agents in Medicinal Chemistry The Treatment Targets of Asthma: From Laboratory to Clinic
Inflammation & Allergy - Drug Targets (Discontinued) Editorial
Current Drug Safety Evaluation of Adverse Drug Event Information in US Manufacturer Labels
Current Drug Safety